» Articles » PMID: 36613515

Dysferlin Deficiency Results in Myofiber-Type Specific Differences in Abundances of Calcium-Handling and Glycogen Metabolism Proteins

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Jan 8
PMID 36613515
Authors
Affiliations
Soon will be listed here.
Abstract

Dysferlinopathies are a clinically heterogeneous group of muscular dystrophies caused by a genetic deficiency of the membrane-associated protein dysferlin, which usually manifest post-growth in young adults. The disease is characterized by progressive skeletal muscle wasting in the limb-girdle and limbs, inflammation, accumulation of lipid droplets in slow-twitch myofibers and, in later stages, replacement of muscles by adipose tissue. Previously we reported myofiber-type specific differences in muscle contractile function of 10-month-old dysferlin-deficient BLAJ mice that could not be fully accounted for by altered myofiber-type composition. In order to further investigate these findings, we examined the impact of dysferlin deficiency on the abundance of calcium (Ca) handling and glucose/glycogen metabolism-related proteins in predominantly slow-twitch, oxidative soleus and fast-twitch, glycolytic extensor digitorum longus (EDL) muscles of 10-month-old wild-type (WT) C57BL/6J and dysferlin-deficient BLAJ male mice. Additionally, we compared the Ca activation properties of isolated slow- and fast-twitch myofibers from 3-month-old WT and BLAJ male mice. Differences were observed for some Ca handling and glucose/glycogen metabolism-related protein levels between BLAJ soleus and EDL muscles (compared with WT) that may contribute to the previously reported differences in function in these BLAJ muscles. Dysferlin deficiency did not impact glycogen content of whole muscles nor Ca activation of the myofilaments, although soleus muscle from 10-month-old BLAJ mice had more glycogen than EDL muscles. These results demonstrate a further impact of dysferlin deficiency on proteins associated with excitation-contraction coupling and glycogen metabolism in skeletal muscles, potentially contributing to altered contractile function in dysferlinopathy.

Citing Articles

Metabolic dysregulation contributes to the development of dysferlinopathy.

Furrer R, Dilbaz S, Steurer S, Santos G, Karrer-Cardel B, Ritz D Life Sci Alliance. 2025; 8(5).

PMID: 40021220 PMC: 11871293. DOI: 10.26508/lsa.202402991.


Skeletal muscle disorders as risk factors for type 2 diabetes.

Tammineni E, Manno C, Oza G, Figueroa L Mol Cell Endocrinol. 2025; 599:112466.

PMID: 39848431 PMC: 11886953. DOI: 10.1016/j.mce.2025.112466.


Pilot investigations into the mechanistic basis for adverse effects of glucocorticoids in dysferlinopathy.

Lloyd E, Crew R, Haynes V, White R, Mark P, Jackaman C Skelet Muscle. 2024; 14(1):19.

PMID: 39123261 PMC: 11312411. DOI: 10.1186/s13395-024-00350-6.

References
1.
Amato A, Brown Jr R . Dysferlinopathies. Handb Clin Neurol. 2011; 101:111-8. DOI: 10.1016/B978-0-08-045031-5.00007-4. View

2.
Kerr J, Ward C, Bloch R . Dysferlin at transverse tubules regulates Ca(2+) homeostasis in skeletal muscle. Front Physiol. 2014; 5:89. PMC: 3944681. DOI: 10.3389/fphys.2014.00089. View

3.
Straub V, Murphy A, Udd B . 229th ENMC international workshop: Limb girdle muscular dystrophies - Nomenclature and reformed classification Naarden, the Netherlands, 17-19 March 2017. Neuromuscul Disord. 2018; 28(8):702-710. DOI: 10.1016/j.nmd.2018.05.007. View

4.
Grounds M, Terrill J, Radley-Crabb H, Robertson T, Papadimitriou J, Spuler S . Lipid accumulation in dysferlin-deficient muscles. Am J Pathol. 2014; 184(6):1668-76. DOI: 10.1016/j.ajpath.2014.02.005. View

5.
Glover L, Brown Jr R . Dysferlin in membrane trafficking and patch repair. Traffic. 2007; 8(7):785-94. DOI: 10.1111/j.1600-0854.2007.00573.x. View